Related Experiment Videos
[Basic fetoprotein (BFP)].
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|April 1, 1986
Summary
Monoclonal antibodies targeting basic fetoprotein (BFP) show enhanced cancer tissue reactivity. A new enzyme immunoassay (MAb-EIA) using these antibodies detected cancer more effectively than conventional methods.
Area of Science:
- Immunology
- Biochemistry
- Oncology
Context:
- Development of specific biomarkers for cancer detection is crucial.
- Hybridoma technology enables production of highly specific monoclonal antibodies.
- Basic fetoprotein (BFP) is a potential tumor marker.
Purpose:
- To produce monoclonal antibodies against basic fetoprotein (BFP).
- To evaluate the immunoreactivity of monoclonal anti-BFP with cancer tissues.
- To develop and validate a monoclonal antibody-based enzyme immunoassay (MAb-EIA) for BFP detection.
Summary:
- Monoclonal antibodies to basic fetoprotein (BFP) were generated using hybridoma technology.
- Immunohistological analysis revealed superior specific immunoreactivity of one monoclonal anti-BFP clone to cancer tissues.
- A competitive enzyme immunoassay (MAb-EIA) was developed using biotin-labeled BFP and peroxidase-conjugated avidin.
- Comparison with a polyclonal antibody-based EIA (PAb-EIA) showed MAb-EIA yielded significantly higher positive detection rates in cancer patients (46.7% vs. 33.8%) while maintaining similar rates in normal and benign disease cohorts.
Impact:
- The developed MAb-EIA demonstrates improved sensitivity for detecting BFP in cancer patients.
- This enhanced assay holds potential for more effective cancer screening and diagnosis.
- Highlights the advantage of monoclonal antibodies over polyclonal antibodies in specific biomarker detection.